Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on ...
In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...
New Understanding of the Gut Immune System May Hold Promise for ... Crohn's disease or ulcerative colitis. Though the two have similar symptoms, they require different ... July 17, 2023 ...
Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on ...
Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options in inflammatory bowel disease, atopic dermatitis, myasthenia gravis and ...
As fires rage in California, more information is coming out air pollution's risk for serious health problems. High levels of fine particles in smoke, burning coal, and from road traffic, called PM2.5 ...
PORTLAND, OR, UNITED STATES, February 7, 2025 /EINPresswire / -- The global ulcerative colitis (UC) market is ex ...
10d
Data presented at the 2025 Crohn’s and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback